Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.14
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-20.6M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$43M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.8%
↓Gross Margin
14.9%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.3%
FCF CAGR
—
FCF margin
-5.9%
FCF / Net income
0.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $53.4M · net income $-5.9M · FCF $-3.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $53.4M | $53.4M | $58.3M | $37.3M | $59.0M |
| Net Income | $-5.9M | $-5.9M | $2.2M | $-9.1M | $-5.1M |
| EBITDA | $-1.4M | $-1.4M | $3.3M | $-8.9M | $-3.5M |
| EPS | — | — | 0.01 | -0.05 | -0.02 |
| Gross Margin | 14.9% | 14.9% | 16.1% | 8.2% | 16.1% |
| Operating Margin | -11.4% | -11.4% | 1.3% | -15.6% | -8.6% |
| Net Margin | -11.0% | -11.0% | 3.8% | -24.3% | -8.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.10 | 0.09 | 0.01 |
| Current Ratio | 6.40 | 6.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.1M | $-3.1M | $-33.5M | $-20.6M | $74072.00 |
| Returns | |||||
| ROE | -6.8% | -6.8% | 2.2% | -9.9% | -8.2% |
| Valuation | |||||
| P/E | — | — | 23.64 | — | — |
| EV/EBITDA | — | — | 17.05 | — | — |
| P/B | 0.49 | 0.49 | 0.53 | 0.69 | 2.27 |
| Growth & Yield | |||||
| Revenue Growth | -8.4% | -8.4% | 56.3% | -36.8% | — |
| EPS Growth | — | — | 124.1% | -164.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → n/d
Residual
-31.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.